{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T10:30:14Z","timestamp":1649068214067},"reference-count":15,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2013,9,1]],"date-time":"2013-09-01T00:00:00Z","timestamp":1377993600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1016\/j.leukres.2013.05.015","type":"journal-article","created":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T13:10:25Z","timestamp":1372165825000},"page":"995-997","source":"Crossref","is-referenced-by-count":1,"title":["\u201cTo switch or not to switch: That is the question\u201d\u2014More than 10% of ratio @ 3 months: How to treat chronic myeloid leukemia patients with this response?"],"prefix":"10.1016","volume":"37","author":[{"given":"Massimo","family":"Breccia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Alimena","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2013.05.015_bib0005","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.1126.1126","article-title":"International randomized study of interferon vs. STI571 (IRIS) 8-year follow-up: sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib","volume":"114","author":"Deininger","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.015_bib0010","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/sj.leu.2403158","article-title":"Imatinib produces significantly superior molecular responses compared to interferon alfa plus cytarabine in patients with newly diagnosed chronic myeloid leukemia in chronic phase","volume":"17","author":"Branford","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.05.015_bib0015","doi-asserted-by":"crossref","first-page":"6315","DOI":"10.1182\/blood-2008-07-166694","article-title":"Delayed achievement of cytogenetic and molecular response is associated with increased risk of progression among patients with chronic myeloid leukemia in early chronic phase receiving high-dose or standard-dose imatinib therapy","volume":"113","author":"Quintas Cardama","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.015_bib0020","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.015_bib0025","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1182\/blood-2012-11-466037","article-title":"Combining BCR-ABL1 transcript levels at 3 and 6 months in chronic myeloid leukemia: implications for early intervention strategies","volume":"121","author":"Neelakantan","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.015_bib0030","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1038\/leu.2012.85","article-title":"Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)","volume":"26","author":"Hanfstein","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.leukres.2013.05.015_bib0035","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2013-03-490128","article-title":"Early responses predicts better outcomes in patients (pts) with newly diagnosed chronic myeloid leukemia (CML): results with four TKI modalities","author":"Jain","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.015_bib0040","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1182\/blood.V118.21.451.451","article-title":"Upfront imatinib therapy in CML patients with rapid switching to nilotinib for failure to achieve molecular targets or intolerance achieves high overall rates of molecular response and a low risk of progression-an update of the TIDEL-II trial","volume":"118","author":"Yeung","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.015_bib0045","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1182\/blood-2011-04-348110","article-title":"The achievement of an early complete cytogenetic response is a major determinant for outcome in patients with early chronic phase chronic myeloid leukemia treated with tyrosine kinase inhibitors","volume":"118","author":"Jabbour","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.015_bib0050","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bjh.12187","article-title":"BCR-ABL1 trancript at 3 months predicts long-term outcomes following second-generation tyrosine kinase inhibitor therapy in the patients with chronic myeloid leukemia in chronic phase who failed imatinib","volume":"160","author":"Kim","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2013.05.015_bib0055","doi-asserted-by":"crossref","first-page":"4323","DOI":"10.1200\/JCO.2011.40.5217","article-title":"Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib","volume":"30","author":"Branford","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2013.05.015_bib0060","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2012-01-407486","article-title":"Predictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib","volume":"120","author":"Marin","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.015_bib0065","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1182\/blood.V120.21.1678.1678","article-title":"The BCR-ABL transcript levels at 3 and 6 months predict the long-term outcome of chronic myeloid leukemia patients treated frontline with imatinib mesylate: a GIMEMA CML WP Analysis","volume":"120","author":"Castagnetti","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.05.015_bib0070","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1182\/blood.V120.21.167.167","volume":"120","author":"Hochhaus","year":"2012","journal-title":"Blood"},{"issue":"Suppl. 1","key":"10.1016\/j.leukres.2013.05.015_bib0075","first-page":"192","article-title":"Molecular response kinetics and bcr-abl reductions in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) receiving dasatinib vs imatinib: DASISION 3-years follow-up","volume":"97","author":"Hochhaus","year":"2012","journal-title":"Haematologica"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613001793?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613001793?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,7,29]],"date-time":"2020-07-29T02:31:45Z","timestamp":1595989905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613001793"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":15,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["S0145212613001793"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.05.015","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,9]]}}}